Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation
作者： Michael D Crowell , Lucinda A Harris
DOI:
关键词: Agonist 、 Chronic idiopathic constipation 、 Internal medicine 、 Irritable bowel syndrome 、 Gastroenterology 、 Medicine 、 Chronic disease 、 Phases of clinical research 、 Chronic constipation 、 Guanylate cyclase C 、 Linaclotide
摘要: Microbia Inc is developing the oral guanylate cyclase C agonist linaclotide, a 14mer peptide for potential treatment of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation. Phase II clinical trials are underway both indications.
elsevier.com参考文章(0)